BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313. [PMID: 11208820 DOI: 10.1200/jco.2001.19.2.305] [Cited by in Crossref: 953] [Cited by in F6Publishing: 228] [Article Influence: 45.4] [Reference Citation Analysis]
Number Citing Articles
1 Brabender J, Vallböhmer D, Grimminger P, Hoffmann AC, Ling F, Lurje G, Bollschweiler E, Schneider PM, Hölscher AH, Metzger R. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg. 2008;12:1815-1821. [PMID: 18769985 DOI: 10.1007/s11605-008-0668-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
2 Rawat S, Kumar G, Kakria A, Sharma MK, Chauhan D. Chemoradiotherapy in the management of locally advanced squamous cell carcinoma esophagus: is surgical resection required? J Gastrointest Cancer 2013;44:277-84. [PMID: 23389866 DOI: 10.1007/s12029-013-9477-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
3 Akutsu Y, Matsubara H, Shuto K, Uesato M, Mori M, Hoshino I, Shiratori T, Miyazawa Y, Ito H, Uno T. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg 2009;33:1002-9. [PMID: 19247705 DOI: 10.1007/s00268-008-9899-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
4 De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, Pinto C, Di Maio M, Farella A, Troiani T. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer. 2011;104:427-432. [PMID: 21245865 DOI: 10.1038/sj.bjc.6606093] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
5 Franco P, Arcadipane F, Strignano P, Spadi R, Trino E, Martini S, Iorio GC, Satolli MA, Airoldi M, Romagnoli R, Camandona M, Ricardi U. Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Med Oncol 2017;34:40. [PMID: 28176241 DOI: 10.1007/s12032-017-0898-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Power DG, Ilson DH. Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 2009;1:145-65. [PMID: 21789119 DOI: 10.1177/1758834009347323] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Duan XF, Tang P, Yu ZT. Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review. Cancer Biol Med. 2014;11:191-201. [PMID: 25364580 DOI: 10.7497/j.issn.2095-3941.2014.03.005] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
8 Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 2021;39:2803-15. [PMID: 34077237 DOI: 10.1200/JCO.20.03611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Herrmann E, Mertineit N, De Bari B, Hoeng L, Caparotti F, Leiser D, Jumeau R, Cihoric N, Jensen AD, Aebersold DM, Ozsahin M. Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. Radiat Oncol 2017;12:97. [PMID: 28615060 DOI: 10.1186/s13014-017-0834-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
10 Law S, Kwong DL, Kwok KF, Wong KH, Chu KM, Sham JS, Wong J. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339-347; discussion 347-348. [PMID: 14501500 DOI: 10.1097/01.sla.0000086545.45918.ee] [Cited by in Crossref: 73] [Cited by in F6Publishing: 88] [Article Influence: 3.8] [Reference Citation Analysis]
11 Gao HJ, Shang XB, Gong L, Zhang HD, Ren P, Shi GD, Wei YC, Yu ZT. Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis. Thorac Cancer 2020;11:243-52. [PMID: 31828980 DOI: 10.1111/1759-7714.13235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Law S, Kwong DL, Wong KH, Kwok KF, Wong J. The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer. J Gastrointest Surg 2006;10:1301-11. [PMID: 17114016 DOI: 10.1016/j.gassur.2006.06.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
13 Krasna MJ. Stage-specific therapy for cancer of the oesophagus: a new 'cancer of the elderly'. Drugs Aging 2009;26:185-94. [PMID: 19358615 DOI: 10.2165/00002512-200926030-00001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Goldfarb M, Brower S, Schwaitzberg SD. Minimally invasive surgery and cancer: controversies part 1. Surg Endosc. 2010;24:304-334. [PMID: 19572178 DOI: 10.1007/s00464-009-0583-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
15 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol 2015;10:518-26. [PMID: 25695222 DOI: 10.1097/JTO.0000000000000457] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008;26:4551-4556. [PMID: 18574157 DOI: 10.1200/jco.2008.16.6918] [Cited by in Crossref: 87] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
18 Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg 2015;149:538-47. [PMID: 25454907 DOI: 10.1016/j.jtcvs.2014.10.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
19 Innocente R, Navarria F, Petri R, Palazzari E, Vecchiato M, Polesel J, Ziccarelli A, Martino A, Ubiali P, Tonin D, Lauretta A, Belluco C, Foltran L, Buonadonna A, Lleshi A, Colombo CB, Barresi L, Gigante M, Franchin G, De Paoli A. Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. Front Oncol 2021;11:626275. [PMID: 33680967 DOI: 10.3389/fonc.2021.626275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Vandenbroucke F, Lozac'h P, Metges JP, Malhaire JP. [Results of surgical resection of squamous cells carcinoma of the oesophagus with or without preoperative radiochemotherapy: comparative and retrospective study]. Ann Chir 2004;129:583-8. [PMID: 15581819 DOI: 10.1016/j.anchir.2004.10.001] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 2009; 15(39): 4962-4968 [PMID: 19842230 DOI: 10.3748/wjg.15.4962] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
22 Chen HS, Hung WH, Ko JL, Hsu PK, Liu CC, Wu SC, Lin CH, Wang BY. Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan. Medicine (Baltimore) 2016;95:e3018. [PMID: 26962818 DOI: 10.1097/MD.0000000000003018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Liu T, Ding S, Dang J, Wang H, Chen J, Li G. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol 2019;14:176. [PMID: 31619265 DOI: 10.1186/s13014-019-1388-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Cáncer de esófago. Medicina Clínica 2008;130:423-8. [DOI: 10.1157/13117853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Liu J, Yue J, Xing L, Yu J. Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer. Front Med. 2013;7:172-179. [PMID: 23681891 DOI: 10.1007/s11684-013-0268-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
26 Betancourt Cuellar SL, Palacio DP, Wu CC, Carter BW, Correa AM, Hofstetter WL, Marom EM. 18FDG-PET/CT is useful in the follow-up of surgically treated patients with oesophageal adenocarcinoma. Br J Radiol 2018;91:20170341. [PMID: 29125331 DOI: 10.1259/bjr.20170341] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Yoon HH, Lowe VJ, Cassivi SD, Romero Y. The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. Gastroenterol Clin North Am. 2009;38:105-120, ix. [PMID: 19327570 DOI: 10.1016/j.gtc.2009.01.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Ding T, Liu C, Huang B, Chu L, Wei L, Lin Y, Luo Y, Zhang B, Hong C, Xu Y, Peng Y. A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. Cancer Manag Res 2021;13:7771-82. [PMID: 34675672 DOI: 10.2147/CMAR.S329687] [Reference Citation Analysis]
29 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149:302-17.e1. [PMID: 25957861 DOI: 10.1053/j.gastro.2015.04.053] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 26.0] [Reference Citation Analysis]
30 Yamashita H, Seto Y, Takenaka R, Okuma K, Kiritooshi T, Mori K, Yamada K, Fukuda T, Kaminishi M, Abe O, Nakagawa K. Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study. PLoS One 2017;12:e0177133. [PMID: 28486551 DOI: 10.1371/journal.pone.0177133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
31 Wijnhoven BP, van Lanschot JJ, Tilanus HW, Steyerberg EW, van der Gaast A. Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses. World J Surg 2009;33:2606-14. [PMID: 19760309 DOI: 10.1007/s00268-009-0223-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
32 Shah RD, Cassano AD, Neifeld JP. Neoadjuvant therapy for esophageal cancer. World J Gastrointest Oncol 2014; 6(10): 403-406 [PMID: 25320656 DOI: 10.4251/wjgo.v6.i10.403] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
33 Li S, Liu H, Diao C, Wang X, Gao M, Li Z, Song L, Gao X, Han J, Wang F, Li W, Han X. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget 2017;8:36339-53. [PMID: 28423740 DOI: 10.18632/oncotarget.16193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
34 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
35 Wang Q, Yu S, Xiao Z, Liu X, Zhang W, Zhang X, He J, Sun K, Xu T, Feng Q, Zhou Z, Wang L, Yin W. Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. Radiat Oncol 2015;10:142. [PMID: 26159510 DOI: 10.1186/s13014-015-0450-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
36 Jackson C, Starling N, Chua YJ, Cunningham D. Pharmacotherapy for oesophagogastric cancer. Drugs 2007;67:2539-56. [PMID: 18034590 DOI: 10.2165/00003495-200767170-00006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Deng J, Wang C, Xiang M, Liu F, Liu Y, Zhao K. Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma. Diagn Pathol. 2014;9:151. [PMID: 25030066 DOI: 10.1186/1746-1596-9-151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
38 Swisher SG, Moughan J, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. J Thorac Oncol 2017;12:368-74. [PMID: 27729298 DOI: 10.1016/j.jtho.2016.10.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
39 Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. BMC Cancer. 2004;4:67. [PMID: 15447791 DOI: 10.1186/1471-2407-4-67] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
40 Jabbour SK, Thomas CR Jr. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol 2010;1:102-11. [PMID: 22811814 DOI: 10.3978/j.issn.2078-6891.2010.013] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
41 Shi Q, Diao Y, Qian J. [Application of Single-hole Thoracoscopic Surgery Combined with ERAS Concept for Respiratory Function Exercise in Perioperative Period of Lung Cancer]. Zhongguo Fei Ai Za Zhi 2020;23:667-72. [PMID: 32434296 DOI: 10.3779/j.issn.1009-3419.2020.101.26] [Reference Citation Analysis]
42 Anvari K, Aledavood SA, Toussi MS, Forghani MN, Mohtashami S, Rajabi MT, Shandiz FH, Nosrati F, Nowferesti G, Salek R. A clinical trial of neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma. J Res Med Sci 2015;20:751-6. [PMID: 26664422 DOI: 10.4103/1735-1995.168377] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
43 Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys 2012;82:1967-72. [PMID: 21507583 DOI: 10.1016/j.ijrobp.2011.01.043] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
44 Fu T, Bu ZD, Li ZY, Zhang LH, Wu XJ, Wu AW, Shan F, Ji X, Dong QS, Ji JF. Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2015;15:322. [PMID: 25928286 DOI: 10.1186/s12885-015-1341-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
45 Jin Z, Zhang J, Chen D, Wu S, Xue P, Zhu K, Xu C, Zhu C, Zhang B. Neoadjuvant chemoradiotherapy, chemotherapy, and radiotherapy do not significantly increase the incidence of anastomotic leakage after esophageal cancer surgery: a meta-analysis. Dis Esophagus 2021:doab089. [PMID: 34952537 DOI: 10.1093/dote/doab089] [Reference Citation Analysis]
46 Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. J Clin Oncol. 2018;36:2796-2803. [PMID: 30089078 DOI: 10.1200/jco.2018.79.1483] [Cited by in Crossref: 142] [Cited by in F6Publishing: 117] [Article Influence: 35.5] [Reference Citation Analysis]
47 Lockhart AC, Reed CE, Decker PA, Meyers BF, Ferguson MK, Oeltjen AR, Putnam JB, Cassivi SD, Montero AJ, Schefter TE; American College of Surgeons Oncology Group. Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Ann Oncol 2014;25:1039-44. [PMID: 24562448 DOI: 10.1093/annonc/mdu091] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
48 Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 2010;28:4714-21. [PMID: 20876421 DOI: 10.1200/JCO.2010.30.7702] [Cited by in Crossref: 92] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
49 Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxì A, Cammà C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30. [PMID: 15194636 DOI: 10.1136/gut.2003.025080] [Cited by in Crossref: 402] [Cited by in F6Publishing: 350] [Article Influence: 22.3] [Reference Citation Analysis]
50 Lo CM, Wang YM, Chen YH, Fang FM, Huang SC, Lu HI, Li SH. The Impact of Radiotherapy Dose in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Curr Oncol 2021;28:1354-65. [PMID: 33805318 DOI: 10.3390/curroncol28020129] [Reference Citation Analysis]
51 Blackham AU, H Naqvi SM, Schell MJ, Jin W, Gangi A, Almhanna K, Fontaine JP, Hoffe SE, Frakes J, Venkat P, Pimiento JM. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer. J Surg Oncol 2018;117:150-9. [PMID: 28833197 DOI: 10.1002/jso.24808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
52 Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243:472-478. [PMID: 16552197 DOI: 10.1097/01.sla.0000208430.07050.61] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 7.8] [Reference Citation Analysis]
53 Jin Z, Chen D, Chen M, Wang C, Zhang B, Zhang J, Zhu C, Shen J. (Neo)adjuvant Chemoradiotherapy is Beneficial to the Long-term Survival of Locally Advanced Esophageal Squamous Cell Carcinoma: A Network Meta-analysis. World J Surg 2021. [PMID: 34482411 DOI: 10.1007/s00268-021-06301-2] [Reference Citation Analysis]
54 Nakanoko T, Saeki H, Morita M, Nakashima Y, Ando K, Oki E, Ohga T, Kakeji Y, Toh Y, Maehara Y. Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol 2014;21:597-604. [PMID: 24065387 DOI: 10.1245/s10434-013-3220-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
55 van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006;94:1389-94. [PMID: 16670722 DOI: 10.1038/sj.bjc.6603134] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
56 Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33:27-37. [DOI: 10.1007/s00259-006-0133-3] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
57 Yuan M, Bao Y, Ma Z, Men Y, Wang Y, Hui Z. The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. Front Oncol 2021;11:628706. [PMID: 33777777 DOI: 10.3389/fonc.2021.628706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Saeki H, Nakashima Y, Zaitsu Y, Tsuda Y, Kasagi Y, Ando K, Imamura Y, Ohgaki K, Ito S, Kimura Y, Egashira A, Oki E, Morita M, Maehara Y. Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today 2016;46:261-7. [PMID: 25740123 DOI: 10.1007/s00595-015-1144-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
59 Wang Y, Wang Q, Zhang N, Ma H, Gu Y, Tang H, Xu Z, Gao Y. Identification of microRNAs as novel biomarkers for detecting esophageal squamous cell carcinoma in Asians: a meta-analysis. Tumour Biol. 2014;35:11595-11604. [PMID: 25135426 DOI: 10.1007/s13277-014-2350-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
60 Ma HF, Lv GX, Cai ZF, Zhang DH. Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis. Onco Targets Ther 2018;11:3441-7. [PMID: 29942136 DOI: 10.2147/OTT.S145063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
61 Shridhar R, Abbott AM, Doepker M, Hoffe SE, Almhanna K, Meredith KL. Perioperative outcomes associated with robotic Ivor Lewis esophagectomy in patient's undergoing neoadjuvant chemoradiotherapy. J Gastrointest Oncol 2016;7:206-12. [PMID: 27034787 DOI: 10.3978/j.issn.2078-6891.2015.104] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
62 Fokas E, Rödel C. Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. Viszeralmedizin 2015;31:347-53. [PMID: 26989391 DOI: 10.1159/000440638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
63 Zhang R, Han D, Li L, Luo W, Liu J, Qian L. EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway. Cancer Manag Res 2020;12:9539-49. [PMID: 33061640 DOI: 10.2147/CMAR.S261182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Yip SS, Coroller TP, Sanford NN, Mamon H, Aerts HJ, Berbeco RI. Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients. Front Oncol 2016;6:72. [PMID: 27066454 DOI: 10.3389/fonc.2016.00072] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
65 Sherman CA, Turrisi AT, Wallace MB, Reed CE. Locally advanced esophageal cancer. Curr Treat Options in Oncol 2002;3:475-85. [DOI: 10.1007/s11864-002-0067-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
66 Fan N, Wang Z, Zhou C, Bludau M, Contino G, Zhao Y, Bruns C. Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis. EClinicalMedicine 2021;42:101183. [PMID: 34805809 DOI: 10.1016/j.eclinm.2021.101183] [Reference Citation Analysis]
67 Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. JAMA Oncol 2018;4:31-8. [PMID: 28975352 DOI: 10.1001/jamaoncol.2017.2805] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
68 Anderson MR, Jankowski JA. Curing oesophageal cancer: one swallow does not make a summer. Eur J Gastroenterol Hepatol 2002;14:1173-5. [PMID: 12439109 DOI: 10.1097/00042737-200211000-00002] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
70 Shinohara ET, Swisher-McClure S, Husson M, Sun W, Metz JM. Esophageal cancer in a young woman with bulimia nervosa: a case report. J Med Case Rep 2007;1:160. [PMID: 18047676 DOI: 10.1186/1752-1947-1-160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
71 Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, Gong L, Yu H, Yang H, Liu J, Lei T, Zhao Q, Mao W. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget 2016;7:50624-34. [PMID: 27244882 DOI: 10.18632/oncotarget.9562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
72 Menges M, Hoehler T. Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward. Gastrointest Tumors 2014;1:99-104. [PMID: 26675677 DOI: 10.1159/000362577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Zhang JL, Wang HY, Yang Q, Lin SY, Luo GY, Zhang R, Xu GL. Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer. World J Gastroenterol 2015; 21(14): 4240-4247 [PMID: 25892874 DOI: 10.3748/wjg.v21.i14.4240] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
74 Smith WH, Pintova S, DiMaio CJ, Manolas P, Lee DS, Hiotis SP, Kartsonis M, Holcombe RF, Dharmarajan KV. An Unusual Course of Metastatic Gastroesophageal Cancer. Case Rep Oncol Med 2015;2015:941508. [PMID: 26770853 DOI: 10.1155/2015/941508] [Reference Citation Analysis]
75 Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Inoue M, Yamamura T. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep 2012;28:446-52. [PMID: 22664791 DOI: 10.3892/or.2012.1847] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
76 Park IH, Kim JY. Surveillance or resection after chemoradiation in esophageal cancer. Ann Transl Med 2018;6:82. [PMID: 29666805 DOI: 10.21037/atm.2017.12.16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med. 2004;2:35. [PMID: 15447788 DOI: 10.1186/1741-7015-2-35] [Cited by in Crossref: 156] [Cited by in F6Publishing: 130] [Article Influence: 8.7] [Reference Citation Analysis]
78 Zheng X, Xing S, Liu XM, Liu W, Liu D, Chi PD, Chen H, Dai SQ, Zhong Q, Zeng MS. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma. BMC Cancer. 2014;14:490. [PMID: 25001061 DOI: 10.1186/1471-2407-14-490] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
79 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
80 Song T, Chen P, Fang M, Zhang X, Du D, Wu S. The Role of Adjuvant Chemoradiotherapy Over Radiotherapy After R0 Resection for Stage II-III Esophageal Squamous Cell Carcinoma. Cancer Manag Res 2020;12:1631-9. [PMID: 32184666 DOI: 10.2147/CMAR.S232930] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005;241:810-817; discussion 817-820. [PMID: 15849517 DOI: 10.1097/01.sla.0000161983.82345.85] [Cited by in Crossref: 112] [Cited by in F6Publishing: 117] [Article Influence: 6.6] [Reference Citation Analysis]
82 Wouters MW, Wijnhoven BP, Karim-Kos HE, Blaauwgeers HG, Stassen LP, Steup WH, Tilanus HW, Tollenaar RA. High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data. Ann Surg Oncol 2008;15:80-7. [PMID: 18004627 DOI: 10.1245/s10434-007-9673-4] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 6.5] [Reference Citation Analysis]
83 Pennathur A, Zhang J, Chen H, Luketich JD. The “best operation” for esophageal cancer? Ann Thorac Surg. 2010;89:S2163-S2167. [PMID: 20494003 DOI: 10.1016/j.athoracsur.2010.03.068] [Cited by in Crossref: 59] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
84 Roh S, Iannettoni MD, Keech J, Arshava EV, Swatek A, Zimmerman MB, Weigel RJ, Parekh KR. Timing of Esophagectomy after Neoadjuvant Chemoradiation Therapy Affects the Incidence of Anastomotic Leaks. Korean J Thorac Cardiovasc Surg 2019;52:1-8. [PMID: 30834211 DOI: 10.5090/kjtcs.2019.52.1.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
85 Imdahl A, Hentschel M, Kleimaier M, Hopt UT, Brink I. Impact of FDG-PET for staging of oesophageal cancer. Langenbecks Arch Surg 2004;389:283-8. [PMID: 15197549 DOI: 10.1007/s00423-004-0492-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
86 Ilson DH. New developments in the treatment of esophageal cancer. Curr Oncol Rep 2002;4:213-21. [PMID: 11937011 DOI: 10.1007/s11912-002-0018-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
87 Wieder HA, Ott K, Lordick F, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA. Prediction of tumor response by FDG-PET: Comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925-1932. [PMID: 17680242 DOI: 10.1007/s00259-007-0521-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
88 Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, de Braud F. Role of BAX for outcome prediction in gastrointestinal malignancies. Med Oncol 2013;30:610. [PMID: 23700226 DOI: 10.1007/s12032-013-0610-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
89 Barreto JC, Posner MC. Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol 2010; 16(30): 3804-3810 [PMID: 20698043 DOI: 10.3748/wjg.v16.i30.3804] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
90 López Carrizosa MC, Samper Ots PM, Rodríguez Pérez A, Sotoca A, Sáez Garrido J, de Miguel MM. High dose rate brachytherapy (HDR-BT) in locally advanced oesophageal cancer. Clinic response and survival related to biological equivalent dose (BED). Clin Transl Oncol 2007;9:385-91. [DOI: 10.1007/s12094-007-0071-y] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
91 Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008; 14(20): 3165-3173 [PMID: 18506920 DOI: 10.3748/wjg.14.3165] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
92 Saeed N, Shridhar R, Hoffe S, Almhanna K, Meredith KL. AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. J Gastrointest Oncol 2016;7:158-65. [PMID: 27034781 DOI: 10.3978/j.issn.2078-6891.2015.067] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
93 Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015;6:39-44. [PMID: 25642336 DOI: 10.3978/j.issn.2078-6891.2014.101] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
94 Park JS, Choi JY, Moon SH, Ahn YC, Lee J, Kim D, Kim K, Shim YM. Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma. Cancer Res Treat 2013;45:22-30. [PMID: 23613667 DOI: 10.4143/crt.2013.45.1.22] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
95 Li Q, Wu SG, Gao JM, Xu JJ, Hu LY, Xu T. Impact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes. J Radiat Res. 2013;54:307-314. [PMID: 23124992 DOI: 10.1093/jrr/rrs096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
96 Hoffmann AC, Vallböhmer D, Prenzel K, Metzger R, Heitmann M, Neiss S, Ling F, Hölscher AH, Schneider PM, Brabender J. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol. 2009;135:1231-1237. [PMID: 19259700 DOI: 10.1007/s00432-009-0564-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
97 Jensen AD, Grehn C, Nikoghosyan A, Thieke C, Krempien R, Huber PE, Debus J, Münter MW. Catch me if you can--the use of image guidance in the radiotherapy of an unusual case of esophageal cancer. Strahlenther Onkol. 2009;185:469-473. [PMID: 19714309 DOI: 10.1007/s00066-009-1935-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
98 Platz TA, Nurkin SJ, Fong MK, Groman A, Flaherty L, Malhotra U, Levea CM, Yendamuri S, Warren GW, Nava HR. Neoadjuvant chemoradiotherapy for esophageal/gastroesophageal carcinoma. J Gastrointest Oncol. 2013;4:137-143. [PMID: 23730509 DOI: 10.3978/j.issn.2078-6891.2013.007] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
99 Li R, Shinde A, Glaser S, Chao J, Kim J, Karam SD, Goodman K, Chen YJ, Amini A. Analyzing the impact of neoadjuvant radiation dose on pathologic response and survival outcomes in esophageal and gastroesophageal cancers. J Gastrointest Oncol. 2019;10:712-722. [PMID: 31392052 DOI: 10.21037/jgo.2019.02.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Cox SJ, O'Cathail SM, Coles B, Crosby T, Mukherjee S. Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Curr Oncol Rep 2017;19:7. [PMID: 28213876 DOI: 10.1007/s11912-017-0559-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol 2016;7:196-205. [PMID: 27034786 DOI: 10.3978/j.issn.2078-6891.2015.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27:857-871. [PMID: 19164214 DOI: 10.1200/jco.2008.17.6297] [Cited by in Crossref: 123] [Cited by in F6Publishing: 75] [Article Influence: 9.5] [Reference Citation Analysis]
103 Kumar P, Damle NA, Bal C. Role of F18-FDG PET/CT in the Staging and Restaging of Esophageal Cancer: A Comparison with CECT. Indian J Surg Oncol 2011;2:343-50. [PMID: 23204793 DOI: 10.1007/s13193-012-0128-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
104 Kumar T, Pai E, Singh R, Francis NJ, Pandey M. Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World J Surg Oncol 2020;18:59. [PMID: 32199464 DOI: 10.1186/s12957-020-01830-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
105 Aledavood SA, Anvari K, Shahidsales S, Hosseini S, Emadi Torghabeh A, Masudian M. Post-neoadjuvant chemoradiotherapy tumor resectability following induction chemotherapy in locally advanced proximal gastric and adenocarcinoma of the esophagogastric junction: A clinical trial. Caspian J Intern Med 2021;12:256-62. [PMID: 34221274 DOI: 10.22088/cjim.12.3.256] [Reference Citation Analysis]
106 Tejani MA, Burtness BA. Multi-modality therapy for cancer of the esophagus and GE junction. Curr Treat Options Oncol 2012;13:390-402. [PMID: 22592595 DOI: 10.1007/s11864-012-0193-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
107 Ghadimi M, Mahmoodi M, Mohammad K, Zeraati H, Rasouli M, Sheikhfathollahi M. Family history of the cancer on the survival of the patients with gastrointestinal cancer in northern Iran, using frailty models. BMC Gastroenterol 2011;11:104. [PMID: 21961837 DOI: 10.1186/1471-230X-11-104] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
108 van de Schoot L, Romme EA, van der Sangen MJ, Creemers GJ, van Lijnschoten G, van Driel OJ, Rutten HJ, Nieuwenhuijzen GA. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol. 2008;15:88-95. [PMID: 17896144 DOI: 10.1245/s10434-007-9582-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
109 Wang DB, Zhang X, Han HL, Xu YJ, Sun DQ, Shi ZL. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci. 2012;57:3226-3233. [PMID: 22695886 DOI: 10.1007/s10620-012-2263-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
110 Sadrizadeh A, Bagheri R, Soltani E, Anvari K, Toussi MS, Moadikhah S. The Comparison of the Advantages of Neoadjuvant Chemoradiotherapy versus Postoperative Chemoradiotherapy: Outcomes in Esophageal Cancer Patients. J Gastrointest Cancer 2018;49:50-6. [PMID: 28025816 DOI: 10.1007/s12029-016-9899-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
111 Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009;87:392-8; discussion 398-9. [PMID: 19161745 DOI: 10.1016/j.athoracsur.2008.11.001] [Cited by in Crossref: 179] [Cited by in F6Publishing: 177] [Article Influence: 13.8] [Reference Citation Analysis]
112 Joseph R, Laks S, Meyers M, McRee AJ. Multidisciplinary Approach to the Management of Esophageal Malignancies. World J Surg 2017;41:1726-33. [PMID: 28361298 DOI: 10.1007/s00268-017-4009-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
113 Kelly MD, Walsh TN. Adjuvant treatment for resectable adenocarcinoma of the oesophagus. ANZ J Surg 2003;73:976-8. [PMID: 14632885 DOI: 10.1046/j.1445-2197.2003.t01-20-.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
114 Saglam S, Arifoglu A, Saglam EK, Tunca F, Asoglu O, Engin G, Yamaner S. Neoadjuvant hyperfractionated-accelerated radiotherapy with concomitant chemotherapy in esophageal cancer: phase II study. J Gastrointest Oncol 2013;4:380-7. [PMID: 24294510 DOI: 10.3978/j.issn.2078-6891.2013.022] [Reference Citation Analysis]
115 Bennett C, Green S, DeCaestecker J, Almond M, Barr H, Bhandari P, Ragunath K, Singh R, Jankowski J. Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus. Cochrane Database Syst Rev 2020;5:CD007334. [PMID: 32442322 DOI: 10.1002/14651858.CD007334.pub5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Hsu PK, Chien LI, Huang CS, Hsieh CC, Wu YC, Hsu WH, Chou TY. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all? Interact Cardiovasc Thorac Surg. 2013;17:460-466. [PMID: 23728085 DOI: 10.1093/icvts/ivt216] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
117 Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. Front Oncol 2012;2:52. [PMID: 22655277 DOI: 10.3389/fonc.2012.00052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 Kunisaki C, Makino H, Takagawa R, Yamamoto N, Nagano Y, Fujii S, Kosaka T, Ono HA, Otsuka Y, Akiyama H, Ichikawa Y, Shimada H. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg 2008;12:802-10. [PMID: 17952515 DOI: 10.1007/s11605-007-0385-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
119 Baba Y, Watanabe M, Yoshida N, Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol 2014; 6(5): 121-128 [PMID: 24834142 DOI: 10.4251/wjgo.v6.i5.121] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
120 Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study. Curr Oncol. 2014;21:125-133. [PMID: 24940093 DOI: 10.3747/co.21.1570] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
121 Huang C, Huang D, Zhu Y, Xie G, Wang H, Shi J, Jia B, Yuan Y, Zhang W. Comparison of a Concurrent Fluorouracil-Based Regimen and a Taxane-Based Regimen Combined with Radiotherapy in Elderly Patients with Esophageal Squamous Cell Carcinoma. Transl Oncol 2020;13:100736. [PMID: 32092670 DOI: 10.1016/j.tranon.2019.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
123 Dan HL, Bai Y, Meng H, Song CL, Zhang J, Zhang Y, Wan LC, Zhang YL, Zhang ZS, Zhou DY. A new three-layer-funnel-shaped esophagogastric anastomosis for surgical treatment of esophageal carcinoma. World J Gastroenterol 2003; 9(1): 22-25 [PMID: 12508344 DOI: 10.3748/wjg.v9.i1.22] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
124 Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-530; discussion 530-531. [PMID: 11573045 DOI: 10.1097/00000658-200110000-00011] [Cited by in Crossref: 266] [Cited by in F6Publishing: 239] [Article Influence: 12.7] [Reference Citation Analysis]
125 Hurmuzlu M, Øvrebø K, Monge OR, Smaaland R, Wentzel-Larsen T, Viste A. High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study. World J Surg Oncol 2010;8:46. [PMID: 20515502 DOI: 10.1186/1477-7819-8-46] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
126 Verma V, Allen PK, Lin SH. Evaluating Factors for Prophylactic Feeding Tube Placement in Gastroesophageal Cancer Patients Undergoing Chemoradiotherapy. Front Oncol 2017;7:235. [PMID: 29021972 DOI: 10.3389/fonc.2017.00235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
127 Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol 2006;8:22-30. [PMID: 16632436 DOI: 10.1007/s12094-006-0091-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
128 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
129 Stahl M, Ruhstaller T. [Combined modality treatment of oesophageal cancer]. Internist (Berl) 2014;55:7-8, 10-4. [PMID: 24154497 DOI: 10.1007/s00108-013-3315-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
130 Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2017;8:219-28. [PMID: 28322515 DOI: 10.1111/1759-7714.12427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
131 Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, Toh Y, Doki Y, Naomoto Y, Nemoto K, Booka E, Matsubara H, Miyazaki T, Muto M, Yanagisawa A, Yoshida M. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1-24. [PMID: 30171413 DOI: 10.1007/s10388-018-0641-9] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 34.5] [Reference Citation Analysis]
132 Feng H, Zhao Y, Jing T, Ma J, Zhao Y, Zhang J, Wang C, Li B. Traditional and cumulative meta-analysis: Chemoradiotherapy followed by surgery versus surgery alone for resectable esophageal carcinoma. Mol Clin Oncol 2018;8:342-51. [PMID: 29435301 DOI: 10.3892/mco.2017.1534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
133 van Rossum PS, van Hillegersberg R, Lever FM, Lips IM, van Lier AL, Meijer GJ, van Leeuwen MS, van Vulpen M, Ruurda JP. Imaging strategies in the management of oesophageal cancer: what's the role of MRI? Eur Radiol. 2013;23:1753-1765. [PMID: 23404138 DOI: 10.1007/s00330-013-2773-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
134 Sugimura K, Motoori M, Yano M, Ishihara R, Hanaoka N, Miyoshi N, Akita H, Goto K, Kobayashi S, Takahashi H, Omori T, Noura S, Ohue M, Fujiwara Y, Sakon M. Endoscopic steroid injection reduced frequency of repeat dilation in patients with anastomotic stenosis after esophagectomy. Esophagus 2016;13:62-7. [DOI: 10.1007/s10388-015-0495-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
135 Mishra S, Ahmad F, Singh S, Singh RK, Das KJM, Kumar S. Assessing failure patterns of radical intent radiation strategies in patients with locally advanced carcinoma of the esophagus. Cancer Rep (Hoboken) 2021;4:e1332. [PMID: 33369258 DOI: 10.1002/cnr2.1332] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Sun X, Martin RCG, Zheng Q, Farmer R, Pandit H, Li X, Jacob K, Suo J, Li Y. Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma. Cell Oncol (Dordr) 2018;41:651-62. [PMID: 30116994 DOI: 10.1007/s13402-018-0399-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
137 Reynolds JV, Preston SR, O'Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O'Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O'Reilly S, O'Dowd G, Leonard G, Hennessy B, Dermott RM. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 2017;17:401. [PMID: 28578652 DOI: 10.1186/s12885-017-3386-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 69] [Article Influence: 15.4] [Reference Citation Analysis]
138 Sugase T, Makino T, Yamasaki M, Tanaka K, Hashimoto T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Mano M, Morii E, Mori M, Doki Y. Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy. Esophagus 2018. [PMID: 29909488 DOI: 10.1007/s10388-018-0626-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14(24): 3773-3780 [PMID: 18609699 DOI: 10.3748/wjg.14.3773] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
140 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
141 Orditura M, Galizia G, Lieto E, De Vita F, Ciardiello F. Treatment of esophagogastric junction carcinoma: An unsolved debate. World J Gastroenterol 2015; 21(15): 4427-4431 [PMID: 25914451 DOI: 10.3748/wjg.v21.i15.4427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
142 Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 2006;11:454-60. [PMID: 17180514 DOI: 10.1007/s10147-006-0610-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
143 Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692. [PMID: 16244542 DOI: 10.1097/01.sla.0000186170.38348.7b] [Cited by in Crossref: 256] [Cited by in F6Publishing: 242] [Article Influence: 15.1] [Reference Citation Analysis]
144 Chen HS, Wu SC, Hsu PK, Huang CS, Liu CC, Wu YC. The Prognostic Impact of Preoperative and Postoperative Chemoradiation in Clinical Stage II and III Esophageal Squamous Cell Carcinomas: A Population Based Study in Taiwan. Medicine (Baltimore) 2015;94:e1002. [PMID: 26107665 DOI: 10.1097/MD.0000000000001002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
145 Leichman LP, Goldman BH, Bohanes PO, Lenz HJ, Thomas CR, Billingsley KG, Corless CL, Iqbal S, Gold PJ, Benedetti JK, Danenberg KD, Blanke CD. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 2011;29:4555-60. [PMID: 22025151 DOI: 10.1200/JCO.2011.36.7490] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 3.1] [Reference Citation Analysis]
146 Zhu Y, Liu M, Yun X, Wang D, Bai Y, Zhang G, Ji B, Jing C. Meta-Analysis for the Therapeutic Effect of Neoadjuvant Therapy in Resectable Esophageal Cancer. Pathol Oncol Res 2017;23:657-63. [PMID: 28013492 DOI: 10.1007/s12253-016-0164-4] [Reference Citation Analysis]
147 Thomaschewski M, Hummel R, Petrova E, Knief J, Wellner UF, Keck T, Bausch D. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World J Gastroenterol 2018; 24(13): 1429-1439 [PMID: 29632424 DOI: 10.3748/wjg.v24.i13.1429] [Reference Citation Analysis]
148 Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2009;100:1725-1730. [PMID: 19436301 DOI: 10.1038/sj.bjc.6605070] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
149 Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows WM, Battafarano RJ, Suntharalingam M. The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. Am J Clin Oncol 2016;39:136-41. [PMID: 24487417 DOI: 10.1097/COC.0000000000000036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
150 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
151 Schulze B, Bergis D, Balermpas P, Trojan J, Woeste G, Bechstein WO, Rödel C, Weiss C. Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncol Lett 2014;7:534-40. [PMID: 24396483 DOI: 10.3892/ol.2013.1709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
152 Reeh M, Nentwich MF, Asani S, Uzunoglu FG, Bockhorn M, Sauter G, Rösch T, Izbicki JR, Bogoevski D. Locally advanced esophageal carcinoma: is there still a role of surgery alone without neoadjuvant treatment? J Gastrointest Surg 2015;19:587-93. [PMID: 25652343 DOI: 10.1007/s11605-015-2762-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
153 Kostakoglu L. FDG-PET Evaluation of Response to Treatment. PET Clin 2008;3:37-75. [PMID: 27158146 DOI: 10.1016/j.cpet.2008.09.001] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
154 Pepek JM, Chino JP, Willett CG, Palta M, Blazer Iii DG, Tyler DS, Uronis HE, Czito BG. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013;8:6. [PMID: 23286735 DOI: 10.1186/1748-717X-8-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
155 Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92. [PMID: 18309943 DOI: 10.1200/JCO.2007.12.9593] [Cited by in Crossref: 860] [Cited by in F6Publishing: 372] [Article Influence: 61.4] [Reference Citation Analysis]
156 Sihag S, Nobel T, Hsu M, Torre S, Tan KS, Janjigian YY, Ku GY, Tang LH, Wu AJ, Maron SB, Bains MS, Jones DR, Molena D. Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter? Ann Surg 2020. [PMID: 33214465 DOI: 10.1097/SLA.0000000000004638] [Reference Citation Analysis]
157 Namm JP, Posner MC. Transhiatal Esophagectomy for Esophageal Cancer. J Laparoendosc Adv Surg Tech A 2016;26:752-6. [PMID: 27548444 DOI: 10.1089/lap.2016.29009.jpn] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Steber C, Hughes RT, McTyre ER, Soike M, Farris M, Levine BJ, Pasche B, Levine E, Blackstock AW. Cisplatin/5-Fluorouracil (5-FU) Versus Carboplatin/Paclitaxel Chemoradiotherapy as Definitive or Pre-Operative Treatment of Esophageal Cancer. Cureus 2021;13:e12574. [PMID: 33575139 DOI: 10.7759/cureus.12574] [Reference Citation Analysis]
159 Gines A, Cassivi SD, Martenson JA Jr, Schleck C, Deschamps C, Sinicrope FA, Alberts SR, Murray JA, Zinsmeister AR, Vazquez-Sequeiros E, Nichols FC 3rd, Miller RC, Quevedo JF, Allen MS, Alexander JA, Zais T, Haddock MG, Romero Y. Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer. Dis Esophagus 2008;21:241-50. [PMID: 18430106 DOI: 10.1111/j.1442-2050.2007.00766.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
160 Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, O'byrne K, Hollywood D, Muldoon C, Reynolds JV. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-9. [PMID: 17024121 DOI: 10.1038/sj.bjc.6603412] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 5.3] [Reference Citation Analysis]
161 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
162 Farhan F, Ghalehtaki R, Mahdavi-Seresht S, Meysamie A, Yamrali M, Farazmand B, Mohammadi N, Saraee E, Mir MR, Mir A, Lashkari M, Salarvand S, Esmati E, Samiei F. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran. J Gastrointest Cancer 2019;50:907-12. [PMID: 30402826 DOI: 10.1007/s12029-018-0155-7] [Reference Citation Analysis]
163 Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Hara J, Yamamura T, Inoue M. Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma. Mol Clin Oncol 2013;1:773-9. [PMID: 24649245 DOI: 10.3892/mco.2013.128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
164 Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of Postoperative Complications After Trimodality Therapy for Esophageal Cancer. International Journal of Radiation Oncology*Biology*Physics 2013;86:885-91. [DOI: 10.1016/j.ijrobp.2013.04.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
165 Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta-analysis. World J Gastroenterol 2009; 15(47): 5983-5991 [PMID: 20014464 DOI: 10.3748/wjg.15.5983] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 72] [Article Influence: 5.9] [Reference Citation Analysis]
166 Haque W, Verma V, Butler EB, Teh BS. Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base. J Gastrointest Oncol 2018;9:80-9. [PMID: 29564174 DOI: 10.21037/jgo.2017.09.12] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
167 Roedl JB, Sahani DV, Colen RR, Fischman AJ, Mueller PR, Blake MA. Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. Eur Radiol. 2008;18:2833-2840. [PMID: 18651155 DOI: 10.1007/s00330-008-1078-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
168 Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007;245:707-16. [PMID: 17457163 DOI: 10.1097/01.sla.0000254367.15810.38] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 7.9] [Reference Citation Analysis]
169 Samuels SE, Stenmark MH, Lee JY, McHugh JB, Hayman JA, Orringer MB, Urba SG, Sun L, Xie C, Kong FM, Cuneo KC. Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes. Adv Radiat Oncol 2017;2:308-15. [PMID: 29114597 DOI: 10.1016/j.adro.2017.05.003] [Reference Citation Analysis]
170 van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg 2008;8:21. [PMID: 19036143 DOI: 10.1186/1471-2482-8-21] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
171 Ma MW, Gao XS, Gu XB, Xie M, Cui M, Zhang M, Liu L, Yin H, Chen LQ. The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma. World J Surg Oncol 2018;16:172. [PMID: 30119684 DOI: 10.1186/s12957-018-1470-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
172 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
173 Cools-Lartigue J, Spicer J, Ferri LE. Current status of management of malignant disease: current management of esophageal cancer. J Gastrointest Surg 2015;19:964-72. [PMID: 25650163 DOI: 10.1007/s11605-014-2701-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
174 Tang H, Zheng H, Tan L, Shen Y, Wang H, Lin M, Wang Q. Neoadjuvant chemoradiotherapy followed by minimally invasive esophagectomy: is it a superior approach for locally advanced resectable esophageal squamous cell carcinoma? J Thorac Dis. 2018;10:963-972. [PMID: 29607169 DOI: 10.21037/jtd.2017.12.108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
175 Orringer MB, Marshall B, Chang AC, Lee J, Pickens A, Lau CL. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246:363-372; discussion 372-374. [PMID: 17717440 DOI: 10.1097/sla.0b013e31814697f2] [Cited by in Crossref: 334] [Cited by in F6Publishing: 92] [Article Influence: 22.3] [Reference Citation Analysis]
176 Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg. 2015;99:270-276. [PMID: 25440267 DOI: 10.1016/j.athoracsur.2014.08.033] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
177 Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 2012;93:207-12; discussion 212-3. [PMID: 21962263 DOI: 10.1016/j.athoracsur.2011.05.021] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
178 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
179 Martin RC 2nd, Brennan MF, Jaques DP. Quality of complication reporting in the surgical literature. Ann Surg. 2002;235:803-813. [PMID: 12035036 DOI: 10.1097/00000658-200206000-00007] [Cited by in Crossref: 433] [Cited by in F6Publishing: 392] [Article Influence: 21.7] [Reference Citation Analysis]
180 Rocha-Filho DR, Peixoto RD, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Di Paula Filho RP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Ribeiro U Jr, Jesus VHF, Costa WL Jr, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience 2021;15:1195. [PMID: 33889204 DOI: 10.3332/ecancer.2021.1195] [Reference Citation Analysis]
181 Zwischenberger JB, Hyde BR, Escalon JC. What's new in general thoracic surgery. J Am Coll Surg 2005;201:90-9. [PMID: 15978449 DOI: 10.1016/j.jamcollsurg.2005.04.028] [Reference Citation Analysis]
182 Maingon P, Manfredi S. Adénocarcinome du bas œsophage et du cardia: prise en charge non chirurgicale. Cancer/Radiothérapie 2001;5:98s-106s. [DOI: 10.1016/s1278-3218(01)80014-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
183 Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan. Ann Thorac Cardiovasc Surg 2016;22:275-83. [PMID: 27384595 DOI: 10.5761/atcs.ra.16-00111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
184 Vošmik M, Kopecký J, John S, Kubeček O, Lochman P, Banni AM, Hruška L, Sirák I. Combined Therapy of Locally Advanced Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. Cancers (Basel) 2021;13:4591. [PMID: 34572818 DOI: 10.3390/cancers13184591] [Reference Citation Analysis]
185 Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010;17:2184-92. [PMID: 20217248 DOI: 10.1245/s10434-010-0995-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 4.4] [Reference Citation Analysis]
186 Huang X, Liu C, Cui Y, Zhang H, Liu Y, Zhou X, Luo J. Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett. 2017;13:704-714. [PMID: 28356949 DOI: 10.3892/ol.2016.5496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
187 Hautmann MG, Kölbl O. [Comparison of recurrence patterns in esophageal carcinoma after surgery alone and surgery after neoadjuvant chemoradiotherapy: a secondary analysis of the CROSS study]. Strahlenther Onkol 2014;190:696-8. [PMID: 25061651 DOI: 10.1007/s00066-014-0682-5] [Reference Citation Analysis]
188 Martin JT, Worni M, Zwischenberger JB, Gloor B, Pietrobon R, D'Amico TA, Berry MF. The role of radiation therapy in resected T2 N0 esophageal cancer: a population-based analysis. Ann Thorac Surg 2013;95:453-8. [PMID: 23063200 DOI: 10.1016/j.athoracsur.2012.08.049] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
189 Boniface C, Deig C, Halsey C, Kelley T, Heskett MB, Thomas CR Jr, Spellman PT, Nabavizadeh N. The Feasibility of Patient-Specific Circulating Tumor DNA Monitoring throughout Multi-Modality Therapy for Locally Advanced Esophageal and Rectal Cancer: A Potential Biomarker for Early Detection of Subclinical Disease. Diagnostics (Basel) 2021;11:73. [PMID: 33466369 DOI: 10.3390/diagnostics11010073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
190 Shepard G, Arrowsmith ER, Murphy P, Barton JH Jr, Peyton JD, Mainwaring M, Blakely L, Maun NA, Bendell JC. A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric Adenocarcinomas. Oncologist 2017;22:1152-e98. [PMID: 28765502 DOI: 10.1634/theoncologist.2017-0186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
191 Abu Hejleh T, DeYoung BR, Engelman E, Deutsch JM, Zimmerman B, Halfdanarson TR, Berg DJ, Parekh KR, Lynch WR, Iannettoni MD, Bhatia S, Clamon G. Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World J Gastrointest Oncol 2012; 4(5): 103-108 [PMID: 22645633 DOI: 10.4251/wjgo.v4.i5.103] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
192 Jiang Y, Kimchi E, Ajani JA. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? Future Oncol 2009;5:157-61. [PMID: 19284374 DOI: 10.2217/14796694.5.2.157] [Reference Citation Analysis]
193 Wang WL, Chang WL, Yang HB, Wang YC, Chang IW, Lee CT, Chang CY, Lin JT, Sheu BS. Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma. Oncotarget 2016;7:71169-81. [PMID: 27036032 DOI: 10.18632/oncotarget.8460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
194 Cellini F, Morganti AG, Di Matteo FM, Mattiucci GC, Valentini V. Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach. Radiat Oncol 2014;9:45. [PMID: 24499595 DOI: 10.1186/1748-717X-9-45] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
195 Ribi K, Koeberle D, Schuller JC, Honegger H, Roth A, Hess V, Moosmann P, von Moos R, Borner M, Lombriser N. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? Support Care Cancer. 2009;Feb 7; Epub ahead of print. [PMID: 19198893 DOI: 10.1007/s00520-008-0570-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
196 Shaikh T, Zaki MA, Dominello MM, Handorf E, Konski AA, Cohen SJ, Shields A, Philip P, Meyer JE. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. Acta Oncol 2016;55:303-8. [PMID: 26581671 DOI: 10.3109/0284186X.2015.1110252] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
197 Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg. 2003;27:1067-1074. [PMID: 12934159 DOI: 10.1007/s00268-003-7063-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
198 Zheng YZ, Zhao W, Hu Y, Ding-Lin XX, Wen J, Yang H, Liu QW, Luo KJ, Huang QY, Chen JY, Fu JH. Aggressive surgical resection does not improve survival in operable esophageal squamous cell carcinoma with N2-3 status. World J Gastroenterol 2015; 21(28): 8644-8652 [PMID: 26229406 DOI: 10.3748/wjg.v21.i28.8644] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
199 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
200 Garces CA, McAuliffe PF, Hochwald SN, Cance WG. Neoadjuvant therapy in the treatment of solid tumors. Curr Probl Surg 2006;43:457-551. [PMID: 16860653 DOI: 10.1067/j.cpsurg.2006.04.003] [Reference Citation Analysis]
201 Makowiec F, Baier P, Kulemann B, Marjanovic G, Bronsert P, Zirlik K, Henke M, Hopt UT, Hoeppner J. Improved long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. J Gastrointest Surg 2013;17:1193-201. [PMID: 23636882 DOI: 10.1007/s11605-013-2212-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
202 Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg 2017;41:1719-25. [PMID: 28271259 DOI: 10.1007/s00268-017-3959-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
203 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
204 Burmeister BH. Role of radiotherapy in the pre-operative management of carcinoma of the esophagus. World J Gastrointest Oncol 2015; 7(1): 1-5 [PMID: 25610538 DOI: 10.4251/wjgo.v7.i1.1] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
205 Wang XB, Jiang XR, Yu XY, Wang L, He S, Feng FY, Guo LP, Jiang W, Lu SH. Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy. Cancer Sci. 2014;105:176-185. [PMID: 24383865 DOI: 10.1111/cas.12331] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
206 Xu Y, Liu J, Du X, Sun X, Zheng Y, Chen J, Li B, Liu W, Jiang H, Mao W. Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. Radiat Oncol 2013;8:116. [PMID: 23656920 DOI: 10.1186/1748-717X-8-116] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
207 Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg. 2017;6:167-174. [PMID: 28447006 DOI: 10.21037/acs.2017.03.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
208 Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist 2015;20:134-42. [PMID: 25561508 DOI: 10.1634/theoncologist.2014-0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
209 Matsubara H. Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol 2008;13:474-8. [PMID: 19093172 DOI: 10.1007/s10147-008-0853-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
210 Purwar P, Bambarkar S, Jiwnani S, Karimundackal G, Laskar SG, Pramesh CS. Multimodality management of esophageal cancer. Indian J Surg 2014;76:494-503. [PMID: 25614726 DOI: 10.1007/s12262-014-1163-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
211 Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev 2017;8:CD010511. [PMID: 28829911 DOI: 10.1002/14651858.CD010511.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
212 Speicher PJ, Wang X, Englum BR, Ganapathi AM, Yerokun B, Hartwig MG, D'Amico TA, Berry MF. Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer. Dis Esophagus 2015;28:788-96. [PMID: 25212528 DOI: 10.1111/dote.12285] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
213 Blazeby JM, Strong S, Donovan JL, Wilson C, Hollingworth W, Crosby T, Nicklin J, Falk SJ, Barham CP, Hollowood AD, Streets CG, Titcomb D, Krysztopik R, Griffin SM, Brookes ST. Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. Br J Cancer 2014;111:234-40. [PMID: 24921919 DOI: 10.1038/bjc.2014.313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
214 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
215 Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL Jr, Frakes J, Adam MA, Sosa JA, Robinson TJ. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. J Gastrointest Surg. 2019;23:885-894. [PMID: 30374818 DOI: 10.1007/s11605-018-4007-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
216 Cheng S, Iannettoni M, Koshy M, Suntharalingam M, Urba S. Squamous cell carcinoma of the esophagus: treat with how many modalities? Semin Oncol 2009;36:493-7. [PMID: 19995639 DOI: 10.1053/j.seminoncol.2009.09.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
217 Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 2011;13:157-67. [PMID: 21365188 DOI: 10.1007/s11912-011-0158-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
218 Yoon HH, Catalano PJ, Murphy KM, Skaar TC, Philips S, Powell M, Montgomery EA, Hafez MJ, Offer SM, Liu G. Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer. 2011;11:176. [PMID: 21586140 DOI: 10.1186/1471-2407-11-176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
219 Wood MD, Zaki BI, Gordon SR, Sutton JE Jr, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. J Thorac Oncol 2013;8:487-94. [PMID: 23370365 DOI: 10.1097/JTO.0b013e3182829bf3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
220 Moehler M, Gockel I, Roessler HP, Arnold D, Trarbach T, Thomaidis T, Klautke G, Rödel C, Brenner B, Lang H. Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. BMC Cancer. 2013;13:75. [PMID: 23394629 DOI: 10.1186/1471-2407-13-75] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
221 Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376-384; discussion 384-385. [PMID: 12192324 DOI: 10.1097/00000658-200209000-00014] [Cited by in Crossref: 181] [Cited by in F6Publishing: 165] [Article Influence: 9.1] [Reference Citation Analysis]
222 Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249-1260. [PMID: 28784312 DOI: 10.1016/s1470-2045(17)30447-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 50] [Article Influence: 20.0] [Reference Citation Analysis]
223 Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376-84; discussion 384-5. [PMID: 12192324 DOI: 10.1097/01.sla.0000027925.23604.5c] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
224 Lin J, Kligerman S, Goel R, Sajedi P, Suntharalingam M, Chuong MD. State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol 2015;6:3-19. [PMID: 25642333 DOI: 10.3978/j.issn.2078-6891.2014.062] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
225 Ma K, Yang Y, Wang S, Yang X, Lu T, Xi J, Jiang W, Zhan C, Zhu Y, Wang Q. Stage selection for neoadjuvant radiotherapy in non-cervical esophageal cancer: A propensity score-matched study based on the SEER database. Thorac Cancer 2018;9:1111-20. [PMID: 29961955 DOI: 10.1111/1759-7714.12794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
226 Kapoor R, Bansal A, Kumar S, Miriyala RT. Factors Influencing Compliance to Radical Treatment of Middle Thoracic Esophageal Cancer: An Audit from a Regional Cancer Centre. Indian J Palliat Care 2016;22:288-94. [PMID: 27559257 DOI: 10.4103/0973-1075.185037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
227 Verma V, Moreno AC, Lin SH. Advances in Radiotherapy Management of Esophageal Cancer. J Clin Med 2016;5:E91. [PMID: 27775643 DOI: 10.3390/jcm5100091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
228 Liu S, Qiu B, Luo G, Liang Y, Zheng Y, Chen Z, Luo K, Xi M, Liu Q, Hu Y, Li Q, Fu J, Liu M, Yang H, Liu H. TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma. J Cancer 2017;8:683-90. [PMID: 28367248 DOI: 10.7150/jca.17048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
229 Kleinberg LR, Catalano PJ, Forastiere AA, Keller SM, Mitchel EP, Anne PR, Benson AB 3rd. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design. Int J Radiat Oncol Biol Phys 2016;94:738-46. [PMID: 26972646 DOI: 10.1016/j.ijrobp.2015.12.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
230 Meng X, Wang L, Zhao Y, Zhu B, Sun T, Zhang T, Gu X, Zheng Z. Neoadjuvant Chemoradiation Treatment for Resectable Esophago-Gastric Cancer: A Systematic Review and Meta-Analysis. J Cancer 2019;10:192-204. [PMID: 30662540 DOI: 10.7150/jca.25915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
231 O'Sullivan KE, Hurley ET, Hurley JP. Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival. Gastroenterol Res Pract 2015;2015:518281. [PMID: 26246803 DOI: 10.1155/2015/518281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
232 Iyer RB, Balachandran A, Bruzzi JF, Johnson V, Macapinlac HA, Munden RF. PET/CT and hepatic radiation injury in esophageal cancer patients. Cancer Imaging 2007;7:189-94. [PMID: 18055293 DOI: 10.1102/1470-7330.2007.0027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
233 Grimm JC, Valero V, Molena D. Surgical indications and optimization of patients for resectable esophageal malignancies. J Thorac Dis. 2014;6:249-257. [PMID: 24624289 DOI: 10.3978/j.issn.2072-1439.2013.11.18] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
234 Chiu PW, Chan AC, Leung SF, Leong HT, Kwong KH, Li MK, Au-Yeung AC, Chung SC, Ng EK. Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005;9:794-802. [PMID: 16187480 DOI: 10.1016/j.gassur.2005.05.005] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 7.1] [Reference Citation Analysis]
235 Wilson KS, Barnett JB, Shah A, Khoo KE. The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer. Curr Oncol 2009;16:9-14. [PMID: 19862357 DOI: 10.3747/co.v16i5.369] [Reference Citation Analysis]
236 Koëter M, van der Sangen MJ, Hurkmans CW, Luyer MD, Rutten HJ, Nieuwenhuijzen GA. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy. Radiat Oncol 2015;10:59. [PMID: 25884226 DOI: 10.1186/s13014-015-0361-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
237 Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol 2015;6:45-52. [PMID: 25642337 DOI: 10.3978/j.issn.2078-6891.2014.054] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
238 Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg 2012;215:643-51. [PMID: 23084493 DOI: 10.1016/j.jamcollsurg.2012.07.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
239 Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. Eur J Cancer 2015;51:2545-52. [PMID: 26321501 DOI: 10.1016/j.ejca.2015.07.044] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
240 Miyazono F, Metzger R, Warnecke-Eberz U, Baldus SE, Brabender J, Bollschweiler E, Doerfler W, Mueller RP, Dienes HP, Aikou T, Hoelscher AH, Schneider PM. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer. 2004;91:666-672. [PMID: 15213712 DOI: 10.1038/sj.bjc.6601976] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
241 Engel S, Awerbuch A, Kwon D, Picado O, Yechieli R, Yakoub D, Portelance L. Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis. J Gastrointest Oncol 2019;10:391-9. [PMID: 31183187 DOI: 10.21037/jgo.2019.01.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
242 Tai P, Yu E. Esophageal cancer management controversies: Radiation oncology point of view. World J Gastrointest Oncol 2014; 6(8): 263-274 [PMID: 25132924 DOI: 10.4251/wjgo.v6.i8.263] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
243 Hyodo I. Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. J Gastroenterol 2006;41:504-6. [PMID: 16799897 DOI: 10.1007/s00535-006-1835-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
244 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
245 Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer H, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2015;18:550-63. [DOI: 10.1007/s10120-014-0403-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
246 Liu B, Bo Y, Wang K, Liu Y, Tang X, Zhao Y, Zhao E, Yuan L. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials. Oncotarget 2017;8:20410-7. [PMID: 28099899 DOI: 10.18632/oncotarget.14669] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
247 Li CY, Huang PM, Chu PY, Chen PM, Lin MW, Kuo SW, Lee JM. Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols. Biomed Res Int 2016;2016:6423297. [PMID: 27777949 DOI: 10.1155/2016/6423297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Semenkovich TR, Samson PP, Hudson JL, Subramanian M, Meyers BF, Kozower BD, Kreisel D, Patterson GA, Robinson CG, Bradley JD, Puri V. Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes? Ann Thorac Surg 2019;107:903-11. [PMID: 30444988 DOI: 10.1016/j.athoracsur.2018.09.064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
249 Meister T, Heinzow HS, Osterkamp R, Wehrmann T, Kucharzik T, Domschke W, Domagk D, Seifert H. Miniprobe endoscopic ultrasound accurately stages esophageal cancer and guides therapeutic decisions in the era of neoadjuvant therapy: results of a multicenter cohort analysis. Surg Endosc. 2013;27:2813-2819. [PMID: 23404148 DOI: 10.1007/s00464-013-2817-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
250 Wang DB, Sun ZY, Deng LM, Zhu DQ, Xia HG, Zhu PZ. Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis. Chin Med J (Engl) 2016;129:2974-82. [PMID: 27958230 DOI: 10.4103/0366-6999.195464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
251 Chang EY, Li X, Jerosch-Herold M, Priest RA, Enestvedt CK, Xu J, Springer CS, Jobe BA. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. J Gastrointest Surg. 2008;12:166-175. [PMID: 17768665 DOI: 10.1007/s11605-007-0253-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
252 Gockel I, Sultanov FS, Domeyer M, Goenner U, Junginger T. Developments in esophageal surgery for adenocarcinoma: a comparison of two decades. BMC Cancer 2007;7:114. [PMID: 17603896 DOI: 10.1186/1471-2407-7-114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
253 Zhou HY, Zheng SP, Li AL, Gao QL, Ou QY, Chen YJ, Wu ST, Lin DG, Liu SB, Huang LY, Li FS, Zhu HY, Qiao GB, Lanuti M, Yao HR, Yu YF. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine 2020;24:100422. [PMID: 32637899 DOI: 10.1016/j.eclinm.2020.100422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]